Chimeric Antigen Receptor T-cell Therapy in Prostate Cancer: Reality or Folly?

A comprehensive review of the current state of the art of chimeric antigen receptor (CAR) T-cell therapy and its clinical application for the treatment of metastatic castration resistant prostate cancer (mCRPC) is well presented by Gorchakov et al [1] in this issue of European Urology. The review underscores the need for an immunologic approach that may capitalize on the ability of a patient’s…

Read the full article here

Related Articles